Concepedia

Author

Sathej Gopalakrishnan

AbbVie (United States)ORCID

Also Known As

S. Gopalakrishnan, Sathej Gopalakrishnan, Sathej M. Gopalakrishnan

33

Publications

1.1K

Citations

11

H-Index

19

Concepts

All Affiliations

AbbVie (United States)AbbVie (Germany)Ain Shams UniversityMerck (Germany)The University of Texas MD Anderson Cancer Center
SG

About

Sathej Gopalakrishnan is an author at AbbVie (United States) specializing in medicine, neurology, and neuroimmunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

115

2

Health Sciences

1

1

44

3

Epidemiology

1

1

17

4

Hepatology

1

1

17

5

Neurology

1

1

54

Sathej Gopalakrishnan

×

11

Publications

993

Citations

11

H-Index

YearCitations

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Andrew H. Wei, Pau Montesinos, Vladimir Ivanov,

Blood

2020

725

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials

Xavier Montalbán, Patrick Vermersch, Douglas L. Arnold,

The Lancet Neurology

2024

54

Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy

Deanna J. Brackman, Doerthe Eckert, Rajeev Menon,

Hematological Oncology

2022

44

Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure‐response analysis

Suresh Agarwal, Sathej Gopalakrishnan, Sven Mensing,

Hematological Oncology

2019

41

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials

Elena Tomaselli Muensterman, Benjamin Engelhardt, Sathej Gopalakrishnan,

Clinical and Translational Science

2021

36

Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma

Apurvasena Parikh, Sathej Gopalakrishnan, Kevin J. Freise,

Leukemia & lymphoma/Leukemia and lymphoma

2017

26

Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection

Sathej Gopalakrishnan, Akshanth R. Polepally, Sven Mensing,

Clinical Pharmacokinetics

2016

17

Asia‐Inclusive Global Development of Enpatoran: Results of an Ethno‐Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial

Lena Klopp‐Schulze, Sathej Gopalakrishnan, Özkan Yalkinoglu,

Clinical Pharmacology & Therapeutics

2024

16

Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis

Nimita Dave, Sathej Gopalakrishnan, Sven Mensing,

Clinical and Translational Science

2019

12

Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia

Sathej Gopalakrishnan, William G. Wierda, Brenda Chyla,

Clinical Pharmacology & Therapeutics

2020

11

Page 1